ES2196530T3 - Compuestos de ruptura para inactivar patogenos. - Google Patents

Compuestos de ruptura para inactivar patogenos.

Info

Publication number
ES2196530T3
ES2196530T3 ES98901776T ES98901776T ES2196530T3 ES 2196530 T3 ES2196530 T3 ES 2196530T3 ES 98901776 T ES98901776 T ES 98901776T ES 98901776 T ES98901776 T ES 98901776T ES 2196530 T3 ES2196530 T3 ES 2196530T3
Authority
ES
Spain
Prior art keywords
blood
nucleic acid
moiety
effector
pathogens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98901776T
Other languages
English (en)
Spanish (es)
Inventor
David Cook
John Merritt
Aileen Nerio
Henry Rapoport
Adonis Stassinopoulos
Susan Wollowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerus Corp
Original Assignee
Cerus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerus Corp filed Critical Cerus Corp
Application granted granted Critical
Publication of ES2196530T3 publication Critical patent/ES2196530T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B01J20/28014—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their form
    • B01J20/28033—Membrane, sheet, cloth, pad, lamellar or mat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/64—Acridine or hydrogenated acridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
ES98901776T 1997-01-06 1998-01-06 Compuestos de ruptura para inactivar patogenos. Expired - Lifetime ES2196530T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77988597A 1997-01-06 1997-01-06
US77983097A 1997-01-07 1997-01-07
US4369697P 1997-04-15 1997-04-15

Publications (1)

Publication Number Publication Date
ES2196530T3 true ES2196530T3 (es) 2003-12-16

Family

ID=27366374

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98901776T Expired - Lifetime ES2196530T3 (es) 1997-01-06 1998-01-06 Compuestos de ruptura para inactivar patogenos.

Country Status (9)

Country Link
EP (1) EP1021414B1 (https=)
JP (2) JP4551502B2 (https=)
CN (2) CN1248245B (https=)
AT (1) ATE243198T1 (https=)
AU (1) AU744089C (https=)
CA (1) CA2276532C (https=)
DE (1) DE69815703T2 (https=)
ES (1) ES2196530T3 (https=)
WO (1) WO1998030545A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243198T1 (de) * 1997-01-06 2003-07-15 Cerus Corp Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen
CN1203900C (zh) 1998-01-06 2005-06-01 塞鲁斯公司 用于淬灭生物材料中病原体灭活剂的方法
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
US7049110B2 (en) 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US7498156B2 (en) 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US7220747B2 (en) 1999-07-20 2007-05-22 Gambro, Inc. Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
US7094378B1 (en) 2000-06-15 2006-08-22 Gambro, Inc. Method and apparatus for inactivation of biological contaminants using photosensitizers
US20020042043A1 (en) * 2000-05-31 2002-04-11 Adonis Stassinopoulos Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
DE10051628B4 (de) * 2000-10-18 2007-06-06 Fresenius Hemocare Beteiligungs Gmbh Einzelsträngiges Oligonukleotid und dessen Verwendung
EP1365750A2 (en) * 2000-12-21 2003-12-03 Cerus Corporation Methods for inactivation of pathogens in biological materials
KR101173871B1 (ko) * 2003-02-06 2012-08-16 앤저 테라퓨틱스 인코퍼레이티드 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
AU2005302256B2 (en) 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
CA2720824C (en) 2008-04-09 2021-09-14 Cerus Corporation Improved quenching methods for red blood cell pathogen inactivation
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN104788373A (zh) * 2015-05-06 2015-07-22 武汉大学 化合物s-303盐酸盐的合成方法
EP3313418B1 (en) 2015-06-26 2024-03-13 Cerus Corporation Cryoprecipitate compositions and methods of preparation thereof
CN104991033A (zh) * 2015-08-05 2015-10-21 上海海虹实业(集团)巢湖今辰药业有限公司 一种采用一测多评法测定川芎挥发油成分的方法
CA3003097A1 (en) 2015-10-23 2017-04-27 Cerus Corporation Plasma compositions and methods of use thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US20190369087A1 (en) 2016-12-23 2019-12-05 Cerus Corporation Systems and methods for testing and screening using compound bound substrates
CA3055203A1 (en) 2017-03-03 2018-09-07 Cerus Corporation Kits and methods for preparing pathogen-inactivated platelet compositions
AU2018395525B2 (en) 2017-12-29 2023-09-14 Cerus Corporation Systems and methods for treating biological fluids
JP7571063B2 (ja) 2019-06-22 2024-10-22 シーラス コーポレイション 生物学的流体の処理を実施するシステム及び方法
US12011510B2 (en) 2019-06-22 2024-06-18 Cerus Corporation Biological fluid treatment systems
CN114269394A (zh) 2019-06-28 2022-04-01 塞鲁斯公司 用于实现生物流体处理装置的系统和方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6402494A (en) * 1993-03-11 1994-09-26 Steritech, Inc. Decontaminating clinical samples
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
DE4444045C2 (de) * 1994-12-10 1997-04-17 Behringwerke Ag Verfahren zur Inaktivierung von Viren mit Hilfe von Acridin oder Acridinderivaten
EP0773716A4 (en) * 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES
ATE243198T1 (de) * 1997-01-06 2003-07-15 Cerus Corp Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen

Also Published As

Publication number Publication date
CA2276532C (en) 2008-06-17
WO1998030545A1 (en) 1998-07-16
HK1026702A1 (en) 2000-12-22
DE69815703T2 (de) 2004-06-03
JP5244083B2 (ja) 2013-07-24
CA2276532A1 (en) 1998-07-16
CN101676268B (zh) 2013-09-25
CN1248245B (zh) 2012-07-04
EP1021414A1 (en) 2000-07-26
DE69815703D1 (de) 2003-07-24
HK1188441A1 (en) 2014-05-02
AU744089B2 (en) 2002-02-14
AU744089C (en) 2003-07-31
JP4551502B2 (ja) 2010-09-29
ATE243198T1 (de) 2003-07-15
CN1248245A (zh) 2000-03-22
JP2010095527A (ja) 2010-04-30
EP1021414B1 (en) 2003-06-18
AU5821798A (en) 1998-08-03
JP2001508449A (ja) 2001-06-26
CN101676268A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
ES2196530T3 (es) Compuestos de ruptura para inactivar patogenos.
BR9815058A (pt) Processo para a preparação de ácidos dialquilfosfìnicos
TR200003829T2 (tr) Bir sulu monoester peroksikarboksilik asit çözeltisinin üretimi için işlem, bu işlem ile elde edilebilen çözelti ve bu çözeltinin dezenfektan olarak kullanımı
ATE225369T1 (de) Doppelsträngige peptidenukleinsäuren
TR199900083T2 (xx) Klaritromisinin kristal bi�imi I.
NO20020348L (no) Peptid acceptor ligeringsmetoder
EP0984800A4 (en) METHOD FOR REDUCING THE TRANSFER POSSIBILITIES OF SPONGIFORM ENCEPHALOPATHY BY BLOOD PRODUCTS
EP1666092A3 (en) Drug combination comprising a fatty acid and a uridine compound.
DK0752997T3 (da) Hidtil ukendte kationiske fosfolipider til transfektion
EP0627225A3 (de) Superabsorbentien und ein Verfahren zu ihrer Herstellung.
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
Reese et al. Oligonucleotide synthesis via phosphotriester intermediates: The phenyl-protecting group
NO20024155L (no) Fremgangsmåte for fremstilling av fosforotioattriestere
ES2153794B1 (es) Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
NZ326283A (en) Diphenyl stilbenes as prodrugs to cox-2 inhibitors
PT1174418E (pt) Processo para a preparacao de gabapentina anidra de grau farmaceutico
UY26494A1 (es) " estabilización de vino"
BR0106831B1 (pt) processo de mono-fosforização de amido, monoéster de fosfato de amido, uso do monoéster de fosfato de amido e composição alimentìcia.
DE69504973D1 (de) Salze von medikamenten
BR9709264A (pt) Processo para produzir e composto
ATE242763T1 (de) Methoximinophenylessigsäureamide
AU7040398A (en) Bis-phosphonate confugates with alkylating moieties having antitumor activity
RU1781222C (ru) О-Этил-S-пропил-о-(2-метоксикарбонил-4-хлорфенил)тиофосфат, обладающий фунгицидной активностью
AR018008A1 (es) Metodo para desactivar secuencias de acidos nucleicos defoliantes en plantas de algodon; vectores o plasmidos y productos que provienen de dichas plantastransformadas